In Brief
INTRODUCTION
The use of antibodies against immune checkpoints, such as CTLA-4 and PD-1/PD-L1, has shown clear clinical benefit for patients with advanced cancer, including melanoma, nonsmall-cell lung cancer (NSCLC), and mismatch repair-deficient (dMMR) colorectal cancer (CRC) (Larkin et al., 2015; Garon et al., 2015; Borghaei et al., 2015; Le et al., 2015 Le et al., , 2017 Overman et al., 2017 Overman et al., , 2018 . Furthermore, the adoptive transfer of ex-vivo-expanded autologous tumor-infiltrating lymphocytes (TILs) has shown impressive clinical responses in melanoma (Rosenberg and Restifo, 2015) and an early clinical signal in cervical cancer (Stevanovi c et al., 2015) . Despite these encouraging results, a large fraction of patients does not respond to current immunotherapies. Treatment failure may be explained at many different levels that include a low number of immunogenic antigens, defective antigen presentation, and/or the expression of alternative immune checkpoint molecules (Blank et al., 2016; Dijkstra et al., 2016; Pitt et al., 2016; Sharma et al., 2017) . Given the large variety in mechanisms of immune evasion by cancers, it is presently challenging to predict whether an individual patient will be sensitive to immunotherapy, what mechanism is likely to underlie resistance, and what alternative treatment could potentially overcome resistance.
Platforms to allow the unbiased and systematic analysis of T cell-mediated tumor recognition on an individual patient basis would greatly contribute to our understanding of the critical factors that determine a successful anti-tumor immune response. Traditionally, ex vivo systems to analyze T cell-tumor interaction have to a very large extent focused on cutaneous melanoma, both because of the availability of robust approaches to expand tumor-infiltrating T cells for this disease (Rosenberg and Restifo, 2015) , and because of the relative ease with which melanoma cell lines can be obtained. Importantly however, with the now widespread clinical development and clinical use of immunotherapy for major epithelial cancers, it is critical to develop technology to dissect T cell-mediated tumor recognition in these tumor types. Traditionally, this effort has been limited by both the low success rate of establishing primary tumor cell lines of epithelial cancers, such as NSCLC and CRC (success rate of 10% or lower) (Dangles-Marie et al., 2007; Zheng et al., 2011) , and the limited feasibility of obtaining matched tumor-reactive T cell populations.
We set out to evaluate the feasibility of an autologous T cell tumor organoid co-culture platform for individual patients. Tumor organoids are three-dimensional primary tumor cell cultures that retain the histological and mutational features of the original tumor. Organoids can be established from surgical tumor resections (e.g., success rate for CRC of 60%-90%) (van de Wetering et al., 2015; Schü tte et al., 2017) and from needle biopsies of metastases (e.g., success rate for CRC of 70%) (Weeber et al., 2015) . In this effort, we wished to establish two things: first, whether tumor-reactive T cells can be obtained by co-culture of peripheral blood lymphocytes (PBLs) with matched tumor organoids; second, whether such T cells can be used to assess the efficiency of tumor cell killing. The use of peripheral blood as a source of tumor-reactive T cells could provide an easily accessible alternative to TILs (Verdegaal et al., 2011) .
Here, we provide proof of concept that co-culture of tumor organoids with PBLs forms an unbiased strategy to obtain tumorreactive T cells from patients with dMMR CRC and NSCLC that kill tumor organoids from the same patient. Our findings provide proof of principle for the generation of a novel class of tumor-specific T cell products, derived from peripheral blood, and provide a means to assess the sensitivity of tumor cells to T cell-mediated attack at the level of the individual patient.
RESULTS

Characterization of a Panel of dMMR CRC Organoids
To evaluate whether tumor-reactive T cells can be enriched by PBLs via stimulation with autologous tumor organoids, we established a clinical protocol that allowed us to withdraw blood and obtain tumor tissue from patients with CRC. We focused on dMMR CRC, given its high mutational load (Cancer Genome Atlas Network, 2012) and frequent response to anti-PD-1 therapy (Le et al., 2015 (Le et al., , 2017 Overman et al., 2017 Overman et al., , 2018 . Fresh tumor tissue was obtained from resection specimens or core-needle biopsies and used for the establishment of organoids. Mismatch repair deficiency was evaluated by an independent pathologist based on expression of mismatch repair proteins according to standard diagnostic criteria (Table 1 ; the STAR Methods). In line with prior data (Weeber et al., 2015; van de Wetering et al., 2015; Schü tte et al., 2017) , the success rate of growing tumor organoids from these sources was 60%. Organoids were expanded from weekly to biweekly passaging at 1:2 to 1:5 split ratios and cryopreserved in low passage master biobanks within 2-9 weeks after derivation. Organoids can be recovered from frozen stocks and expanded for several months to large numbers without loss of proliferative capacity.
We established a panel of 15 tumor organoids from 13 different patients with dMMR CRC (Table 1 ). The organoids morphologically reflected the original tumor they were derived from ( Figures 1A and S1 ). Whole-exome sequencing (WES) of tumor organoids showed a high mutational burden (median = 1,938 non-synonymous mutations per tumor, range 795-2,877), well in the range previously reported for hypermutated CRC ( Figure 1B ) (TCGA, 2012; Vogelstein et al., 2013) . Mutations typically associated with hypermutated CRC (TCGA, 2012) were also represented in these organoids ( Figure 1C ; Table S1 ). Considering that loss of major histocompatibility complex class I (MHC class I) occurs in up to 60% of dMMR CRC (Dierssen See also Figures S1 and S2 and Tables S1 and S2. et al., 2007), we screened for MHC class I expression after stimulation with interferon-gamma (IFNg) and identified 9 MHCclass-I-proficient tumor organoids from eight patients (62% of organoid samples) ( Figures 1D and S2 ). MHC class I expression of tumor organoids correlated with immunohistochemistry data of MHC class I expression of the tumor they were derived from (Spearman r = 0.78; p = 0.01) ( Figure S2 ; Table S2 ). Most importantly, tumor organoids classified as MHC class I deficient were always derived from MHC class I deficient tumors, indicating that loss of MHC class I is not a general feature of organoid culture.
Induction of Tumor Reactivity in Circulating T Cells by Co-culture with Autologous Tumor Organoids
To test whether tumor organoids may be used to obtain tumor reactive T cells, we selected MHC class I proficient tumor organoids and focused on the peripheral blood compartment as a source of T cells with a lower degree of exhaustion. Prior to co-culture with autologous T cells, tumor organoids were prestimulated with IFNg to enhance antigen presentation. IFNg exposure also led to the induction of PD-L1, a negative regulator of T cell activation ( Figure 1E ), and to counteract any inhibitory effect of PD-L1 during T cell activation, we added blocking antibodies to PD-1. Plate-bound anti-CD28 and interleukin-2 (IL-2) were added to provide co-stimulation and to support T cell proliferation, respectively. Peripheral blood mononuclear cells (PBMCs) were isolated from patients with dMMR CRC and stimulated weekly with autologous tumor organoids ( Figure 2A ). Tumor recognition by CD8 + T cells was evaluated at baseline and after 2 weeks of co-culture by staining for IFNg and the degranulation marker CD107a. In 4 of 8 (50%) patients with MHC class I + tumor organoids, stimulation with autologous tumor organoids induced both IFNg secretion and CD107a upregulation in CD8 + T cells after 2 weeks of co-culture ( Figures 2B and 2C ). Responses were never observed in MHC class I deficient lines (data not shown). The magnitude of the response varied between patients, including small, but reproducible, responses of 1%-3% tumorreactive CD8 + T cells, as well as a patient of whom 50% of all CD8 + T cells were tumor reactive. The high reactivity for CRC-9 suggested the presence of a pre-existing tumor-reactive T cell population. We therefore evaluated tumor reactivity of T cells before co-culture with tumor organoids (i.e., directly after isolation from blood). A substantial proportion of CD8 + T cells from patient CRC-9 was already tumor reactive, and this population increased approximately 10-fold in frequency upon 2 weeks of co-culture ( Figures 2D and 2E ). In contrast, T cells from patients CRC-11, CRC-12, and CRC-13 did not show any detectable tumor reactivity before organoid co-culture (Figure 2E) , indicating that T cell organoid co-culture systems also can be used to expand previously undetectable tumor-reactive T cell populations.
Induction of Tumor Reactivity in Circulating T Cells from Patients with NSCLC
We then assessed whether our strategy to obtain tumor-reactive T cell populations from peripheral blood by organoid co-culture also could be applied to non-small cell lung cancer. As compared to dMMR CRC, mutational burden of NSCLC is approximately 5-fold lower (Vogelstein et al., 2013; Govindan et al., 2012) and response to PD-1/PD-L1 blockade is restricted to approximately 20% of patients (Garon et al., 2015; Borghaei et al., 2015) . We generated NSCLC organoids from six patients (Figures 3A and S3 ; Table S3 ), using a method similar to that established for CRC organoids (Sachs et al., 2018) . Sample NSCLC-3 contained both normal airway epithelial organoids that grew as cystic thin-walled organoids and tumor organoids that showed a more solid morphology. To select for tumor organoids, we applied the MDM-2 inhibitor Nutlin-3a to selectively grow out p53 mutant cells of this sample, resulting in a pure tumor organoid population (Sachs et al., 2018) . All NSCLC organoids were MHC class I proficient and expressed various levels of PD-L1 upon stimulation with IFNg ( Figures 3B and 3C) . In vitro exposure of PBMCs to autologous tumor organoids resulted in the expansion of tumor-reactive CD8 + populations in two of these patients after 2 weeks of co-culture ( Figures 3D and 3E) . Notably, none of these responses could be consistently detected before co-culture with organoids ( Figure 3F ). Collectively, these data demonstrate the feasibility of inducing patientspecific tumor-reactive T cell responses by co-culture of PBMCs and autologous tumor organoids in two epithelial tumor types.
Specificity of Organoid-Reactive T Cell Responses
Next, we wished to evaluate whether the T cell responses induced by organoid co-culture are truly tumor-specific or should be considered artifacts of organoid culture or IFNg treatment. Specifically, while IFNg enhances antigen processing and presentation, it also induces expression of a large number of genes, potentially allowing the formation of T cell responses against (self-)antigens not expressed in the absence of IFNg.
To evaluate the dependency of tumor organoid-reactive T cell responses on IFNg, we compared T cell expression of the activation marker CD137 upon stimulation with tumor organoids that were either pre-stimulated with IFNg or left untreated ( Figure 4A ).
For 4 of 5 cases tested, similar CD8 + T cell responses were induced toward tumor organoids regardless of IFNg pre-stimulation. To more directly assess whether the induced T cell responses were specific for tumor antigens, we tested whether T cells also responded to stimulation with organoids of autologous normal tissue, and whether T cells responded to stimulation with autologous tumor digest. To assess restriction of T cell reactivity to the tumor organoid used for T cell induction, we established normal colon or lung organoids from two patients (CRC-12 and NSCLC-3). In addition, we generated organoids of a synchronous mismatch repair-proficient (pMMR) CRC from patient CRC-13, from whom we also had obtained a dMMR CRC. In all cases, T cell reactivity was restricted to the tumor organoids to which reactivity had been induced in the 2-week co-culture with PBLs; i.e., no reactivity was observed against normal tissue or pMMR CRC organoids ( Figures 4B-4G ).
For two patients, single-cell digest of autologous tumor tissue was also available to stimulate organoid-reactive T cells (Figures 4F and 4G) . T cells reactive to NSCLC-3 organoids were also reactive to tumor digest but not to normal lung digest. In contrast, T cells reactive to NSCLC-1 organoids did not produce IFNg upon stimulation with autologous tumor digest. While the relatively low level of reactivity toward NSCLC-1 organoids limits the ability to detect subtle reactivity toward tumor digest, at this stage we cannot rule out that T cell reactivity in this sample is directed against organoid-specific targets. Taken together with the experiments in which we evaluated reactivity toward control organoids, this indicates that for 3 out of 4 tested samples, induced CD8 + T cell responses are tumor specific. At the same time, it also highlights the value of generating organoids from non-malignant tissue that can serve as controls. See also Figure S3 and Table S3 . Figure 5B). Since we only observed cross-reactivity to control organoids for CD4 + T cells and not for CD8 + T cells, we hypothesized this may be directed against foreign antigens derived from the extracellular environment. Organoids are cultured in murine basement membrane matrix (Geltrex), and consequently murine antigens could be presented to T cells. To address this hypothesis, we generated monocyte-derived dendritic cells (moDCs) from PBMCs of patient CRC-1 and loaded these with Geltrex or irradiated cells of tumor or healthy colon organoids. CD4 + T cell reactivity was only induced by stimulation with Geltrex-loaded DCs or organoids grown in Geltrex ( Figure 5C ). In addition, reactivity was largely abolished when organoids were grown in the absence of Geltrex for 3 days (Figures 5C and S4) . This indicates that co-culture systems involving Geltrex can induce CD4 + T cell reactivity not directed against tumor antigens. Of note, strategies to expand organoids in synthetic matrices have been described recently (Gjorevski et al., 2016) and could serve as alternatives to bypass reactivity to animal antigen.
Tumor Organoids Are Killed by Autologous TumorReactive T Cells
Having established the feasibility of inducing autologous tumorreactive CD8 + T cell products for a substantial fraction of patients, we next aimed to determine whether organoid systems can be used to assess the efficiency of tumor destruction by these T cells. To determine this, we co-cultured tumor organoids with autologous tumor-reactive T cell populations for 3 days and quantified the number of live tumor cells by flow cytometry. For all samples tested, exposure of tumor organoids to autologous T cells led to substantially reduced survival ( Figure 6A ). Addition of MHC class I blocking antibodies rescued tumor cell survival, demonstrating the presence of an antigen-specific CD8 + T cell response. To visualize the cytolytic activity of tumor-reactive T cells, we labeled NSCLC-1 organoids with a tracer dye and imaged them in the presence of a green fluorescent apoptosis probe detecting active caspase-3/7 (''caspase-3/7 probe'') ( Figure 6B ). Addition of autologous T cells led to reduced organoid size and was accompanied by widespread apoptosis.
To provide further evidence for the specificity of tumor cell killing by autologous T cells, we performed parallel cytotoxicity assays with tumor and healthy organoids of NSCLC-3. T cells were first expanded using the rapid expansion protocol previously established to generate TIL products for adoptive cell therapy (Dudley et al., 2003) . T cells efficiently killed tumor organoids, but did not affect survival of healthy organoids ( Figure 6C ). Live imaging showed strong T cell mediated killing of tumor organoids when incubated with autologous T cells (Figures 6D and  S5 ; Video S1). Tumor organoids cultured without T cells (Video S2) or with T cells in the presence of blocking antibodies to MHC class I and MHC class II (Video S3) continued to proliferate. As a further control, healthy organoids continued proliferation regardless of the presence of T cells (Figures 6D and S5 ; Videos S4, S5, and S6). Taken together, these data demonstrate that organoids of epithelial tumors can be used to measure the rate of destruction by autologous T cells. This platform should provide a valuable tool to compare e.g., the relative contribution of different cancer (neo-)antigens to T-cell-mediated killing, assess how the genetic state of tumor cells influences sensitivity to T cell attack, and test the value of strategies to increase this sensitivity.
DISCUSSION
The potential of patient-specific model systems for the implementation of personalized medicine in the field of targeted therapy is considered substantial (Horvath et al., 2016) . We speculate that the value of patient-specific model systems will prove even higher in the field of immuno-oncology, given the inherent diversity in human leukocyte antigen (HLA) and T cell receptor (TCR) genes, the private nature of the neo-antigens that are expressed in human cancers, and the multifactorial nature of T cell-mediated tumor destruction. Much of our current understanding of T cell recognition in human cancer has been based on work in melanoma, and robust systems to measure T cell tumor interactions in a patient-specific manner, to our knowledge, have not been described for epithelial cancers. Here, we provide proof of concept that tumor organoids can be used to establish individualized ex vivo model systems to support T cell-based therapies and to study the interactions between T cells and tumor cells. We foresee two major applications for the platform that we describe. First, it will allow one to mechanistically dissect the pathways that determine tumor cell sensitivity and resistance to immunotherapy. Second, it opens the possibility to generate patient-specific T cell products in an unbiased manner. With respect to the former application, the ability to establish tumor organoid cultures from very limited amounts of tumor (such as needle biopsies), combined with the potential to expand circulating tumor-reactive T cells from peripheral blood, provides a minimally invasive means to interrogate tumor sensitivity to immunotherapy for individual patients at different time points during treatment. For patients who initially responded to treatment with immune checkpoint inhibitors but eventually relapse, the establishment of co-cultures based on paired (tumor and blood) biopsies before and after relapse should provide a unique assay system for the functional dissection of the underlying cause of relapse. Recent genetic studies on paired biopsies have demonstrated the power of such an approach in a small set of melanoma patients who relapsed while on anti-PD1 therapy, demonstrating the acquisition of JAK1/2 mutations as one cause of resistance (Zaretsky et al., 2016) . It will be of interest to determine whether a similar reduced sensitivity to T cell attack by JAK1/2 mutations is selected for in epithelial cancers. In addition to the analysis of natural and therapy-induced variation in tumor cell sensitivity to T cell pressure, there is increasing interest in the use of small molecules and antibodies to enhance tumor cell sensitivity to T cell attack (Patel and Minn, 2018) . Parallel tumor organoid T cell cultures in the presence or absence of drugs of interest should form a straightforward system to identify suitable candidates for combination with immunotherapy.
With respect to the second potential application of this platform, the ability to expand circulating tumor-reactive T cells by co-culture with tumor organoids provides a clinically feasible T cells were obtained by 2-week co-culture with autologous tumor organoids and, where indicated (by a lowercase ''e''), further expanded using a rapid expansion protocol (Dudley et al., 2003) , in some cases preceded by CD137-based enrichment of tumor-reactive cells (indicated by an uppercase ''E'').
(A) Quantification of organoid killing upon T cell co-culture. After 3 days of co-culture, organoids were dissociated into single cells and the number of live cells was quantified using flow cytometry in the presence of counting beads. Where indicated, MHC class I or MHC class II was blocked with W6/32 or Tü 39 antibody, respectively. *p < 0.05; **p < 0.01; and ***p < 0.001; Student's t test. Error bars represent SEM of at least two biological replicates.
(legend continued on next page) strategy for the generation of patient-specific T cell products for adoptive T cell transfer. This approach bypasses the need for samples derived from resection specimens to isolate tumor-infiltrating lymphocytes. In our proof-of-concept study, tumor-reactive CD8 + T cells were expanded from the circulation in 4 of 13 dMMR CRC patients (31%) and 2 of 6 NSCLC patients (33%). When considering only MHC-class-I-proficient dMMR CRC patients, tumor-reactive T cells were induced in 50% of samples, highlighting the need for strategies to revert or bypass MHC I loss as an immune escape mechanism. Larger sample sizes will be needed to more precisely define the success rate of this approach. Moreover, in this study we focused on tumor types with high mutational load, and it will be important to determine whether the feasibility of inducing tumor-reactive T cells can be extended to poorly immunogenic cancers, such as mismatch repair-proficient CRC. In parallel, efforts to further increase the success rate of this approach could focus on strategies to improve selection of circulating tumor-reactive T cells, e.g., based on PD-1 expression by T cells (Gros et al., 2016) .
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Peripheral blood lymphocytes
The peripheral blood mononuclear cells (PBMC) fraction was isolated from peripheral blood by Ficoll-Paque density gradient separation and cryopreserved until later use.
Organoid line authentication DNA was isolated from master and working biobanks of organoids and patient-matched peripheral blood using a DNEasy kit (QIAGEN). Samples were genotyped using a Taqman-based SNParray targeting 26 SNPs (Hartwig Medical Foundation, Amsterdam). An identity score was calculated as described by (Tanabe et al., 1999) and (Liang-Chu et al., 2015) . When comparing two samples, for each locus where both samples had called alleles, the number of distinct alleles in each individual sample, as well as the number of shared alleles was computed. These were summed across all loci and an identity score was computed defined as 2x the number of shared alleles total distinct alleles sample 1 + total distinct alleles sample 2 :
A threshold of 0.9 of the summed identity score was defined as a cut-off and organoid lines that did not match to autologous blood were discarded. Two samples (NSCLC-3 and NSCLC-5), showed identity scores < 0.9 in comparison with autologous blood, but showed exclusively heterozygous to homozygous changes in the tumor, suggesting loss of heterozygosity due to copy number aberrations. We authenticated these lines by performing HLA-typing by PCR (Sanquin, Amsterdam) or based on whole genome sequencing data by Optitype (Szolek et al., 2014) .
METHOD DETAILS
Organoid -lymphocyte co-culture Culture media for PBMC was composed of RPMI 1640 (GIBCO), supplemented with 2 mM Ultraglutamine I, 1:100 penicillin/streptomycin and 10% male human AB serum (Sigma-Aldrich) (''T cell medium''). One day before co-culture, PBMC were thawed in pre-warmed (37 C) T cell medium (human serum was replaced with FCS during thawing) and incubated for 15 min with 25 U/mL benzonase (Merck). After washing, cells were resuspended at 2-3*10 6 cells/mL in T cell medium supplemented with 150 U/mL IL-2 and cultured overnight at 37 C. Prior to co-culture, tumor organoids were stimulated overnight with 200 ng/mL human recombinant IFNg (Peprotech). 96-well U-bottom plates were coated with 5 mg/mL anti-CD28 (clone CD28.2, eBioscience) and kept overnight at 4 C. The next day, tumor organoids were dissociated to single cells with TrypLE Express and resuspended in T cell medium. Anti-CD28-coated plates were washed twice with PBS and PBMC were seeded at a density of 10 5 cells/well and stimulated with single celldissociated organoids at a 20:1 effector:target ratio. Co-cultures were performed in the presence of 150 U/mL IL-2 and 20 mg/mL anti-PD-1-blocking antibody (kindly donated by Merus, Utrecht). Half of the medium, including IL-2 and anti-PD-1, was refreshed two to three times per week. Every week, PBMC were collected, counted, and replated at 10 5 cells/well, and re-stimulated with fresh tumor organoids.
Flow cytometry
For evaluation of MHC-I and PD-L1 expression by tumor organoids, organoids were dissociated to single cells using TrypLE Express, with or without overnight pre-incubation with 200 ng/mL IFNg. Tumor cells were washed in FACS buffer (PBS + 5 mM EDTA + 1% bovine serum antigen) and stained with mouse anti-human HLA-A,B,C-PE (BD Bioscience) or anti-CD274-APC (eBioscience) antibodies, or isotype controls (PE mouse IgG1, kappa (BD) and APC mouse IgG1 kappa (eBioscience)) for 30 min at 4 C. Cells were washed twice with FACS buffer and DAPI was added to exclude dead cells prior to recording at a Becton Dickinson Fortessa or LSRII flow cytometer.
For evaluation of tumor reactivity, 10 5 PBMC were restimulated with tumor organoids at a 2:1 effector: target ratio and seeded in anti-CD28-coated plates in the presence of 20 mg/mL anti-PD-1 and co-cultured for 5 hr. Mouse anti-human CD107a-PE antibodies (BD) were added at the start of co-culture. Golgi-Plug (1:1000, BD) and Golgi-Stop (1:1500, BD) was added after 1 hr and coculture continued for an additional 4 hr. Cells were washed twice in FACS buffer and stained with the following antibodies: anti-CD3-PerCP-Cy5.5 (BD), anti-CD4-FITC (BD), anti-CD8-BV421 (BD), and near-IR viability dye (Life technologies) for 30 min at 4 C. Cells were washed twice in FACS buffer, fixed, and stained for intracellular IFNg (anti-IFNg-APC, BD) using the Cytofix/Cytoperm kit (BD), according to manufacturer's instructions. PBMC stimulated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA, SigmaAldrich) and 1 mg/mL ionomycin (Sigma-Aldrich) served as positive controls and PBMC cultured without tumor stimulation as negative controls. In some experiments, PBMC and tumor cells were co-cultured for 24 hr before staining with anti-CD3-PerCP-Cy5.5, anti-CD4-FITC, anti-CD8-PB, anti-CD137-APC (BD) and near-IR viability dye.
Rapid expansion of unselected T cells or tumor-reactive sublines T cells from patient CRC-12, NSCLC-1 and NSCLC-3 were co-cultured for two weeks with autologous tumor organoids and expanded for two weeks in the presence of irradiated (40 Gy, Gamma Cell-40) pooled PBMC from three healthy donors (1:200 T cell:feeder ratio), 3000 U/mL IL-2 and 30 ng/mL anti-human CD3 (OKT-3, eBioscience). After 5-7 days, medium, including IL-2, was refreshed every 2-3 days. For expansion of tumor-reactive sublines, T cells were sorted on the basis of CD137 expression 24 hours after stimulation with tumor organoids, using a CD137 Microbead Kit (Miltenyi) following manufacturer's instructions and expanded as described above.
Organoid killing assays
To determine the sensitivity of tumor organoids to T cell-mediated killing, flat-bottom non-tissue culture-treated plates were coated with 5 mg/mL anti-CD28 and kept at 4 C overnight prior to co-culture. Organoids were stimulated with 200 ng/mL IFNg for 24h prior to co-culture. The next day, organoids were isolated from Geltrex by density gradient separation. Part of the organoids were dissociated to single cells and counted using a hemocytometer. This was used to infer the number of tumor cells per tumor organoid to allow coculture of organoids and T cells at a 5:1 effector:target ratio. Next, tumor organoids were resuspended in T cell medium. T cells were collected after two weeks of co-culture with tumor organoids and resuspended in T cell medium. Anti-CD28-coated plates were washed twice with PBS and organoids were seeded in triplicate without T cells or with 5*10 4 autologous T cells obtained by two weeks of organoid co-culture. To block MHC class I and II, organoids were pre-incubated for 30 min with 50 mg/mL pan-MHC-I blocking antibody W6/32, or pan-MHC-II blocking antibody Tü 39 (blocking antibody remained present throughout the co-culture).
To facilitate visualization, organoids were in some cases stained with 1 mM of CellTrace Yellow (Invitrogen) and T cells with 100 nM CellTrace FarRed (Invitrogen) in PBS for 20 min at 37 C followed by blocking with human serum and washing in PBS. At the start of co-culture, a green-fluorescent caspase 3/7 probe that binds DNA upon cleavage by caspase 3/7 (referred to as ''caspase 3/7 probe'') (Biotium) was added at 1:2000 dilution to visualize cells undergoing apoptosis. After 3 days of co-culture, organoids and PBMC were collected and dissociated into single cells with TrypLE Express, combined with regular resuspension and vortexing. Care was taken to limit the reaction until the moment organoids were fully dissociated. 7.46 mm AccuCount blank counting beads (Spherotech) were added to each well, cells were washed in FACS buffer and stained with anti-CD3-AF700 (Invitrogen) and anti-CD326-PE-Cy7 (Biolegend) for 30 min at 4 C. Organoids or T cells labeled with CellTrace dyes were not stained with antibodies. Cells were washed twice and stained with DAPI to mark dead cells prior to flow cytometric recording.
Immunohistochemistry
Organoids were recovered from Geltrex by density gradient separation (centrifugation at 300 g, 5 min, 4 C in cold basal organoid culture medium) when they reached an approximate diameter of 100 mm, fixed in 4% paraformaldehyde for 30 min at room temperature or overnight at 4 C, pelleted, and embedded in paraffin blocks. In some cases, organoids were isolated from Geltrex using 10 mg/mL dispase type II (Sigma) or Cell Recovery Solution (Corning). Immunohistochemistry of samples was performed on a BenchMark Ultra autostainer (Ventana Medical Systems). Briefly, paraffin sections were cut at 3 mm, heated at 75 C for 28 min and deparaffinized in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems) for 32 min at 95 C. P53 was detected using clone DO-7 (1:7000 dilution, 32 min at 37 C, Agilent Technologies), and MHC-I using clone HCA2 (1:5000 dilution, 32 min at 37 C, Nordic Mubio) and clone HC10 (1:20000 dilution, 32 min at 37 C, Nordic Mubio). For HCA2 signal amplification was applied using the Optiview Amplification Kit (4 min, Ventana Medical Systems). Bound antibody was detected using the OptiView DAB Detection Kit (Ventana Medical Systems). Slides were counterstained with Hematoxylin and Bluing Reagent (Ventana Medical Systems). For assessment of mismatch repair status, immunohistochemistry was performed according to standard protocols for the Ventana automated immunostainer. (MLH1, clone M1, Roche; MSH2, clone G219-1129, Roche; MSH6, clone EP49, Abcam; PMS2, clone EP51, Agilent Technologies).
Whole exome DNA sequencing At least 200 ng of genomic DNA was extracted from CRC organoids and patient-matched PBMC using a DNEasy kit (QIAGEN). After exome capture (Integrated DNA Technologies probe set), whole-exome sequencing was performed on an Illumina HiSeq DNA analyzer using 100 bp paired-end reads.
T cell recognition assays of Geltrex Tumor or healthy organoids were isolated from Geltrex using 10 mg/mL dispase type II (Sigma) and cultured in organoid medium for three days with 10 mM Y-27632 (Cayman Chemicals) in 6-well plates. In some cases, two days later, 100 mL/well Geltrex was added to organoids. After three days, organoids were used in tumor recognition assays as described under flow cytometry.
Monocytes were sorted on the basis of CD14 on a MoFlo Astrios flow cytometer and cultured in GMP DC medium (CellGenix) with 800 U/mL GM-CSF and 400 U/mL IL-4 (CellGenix). Five days after differentiation, DCs were matured with GM-CSF, IL-4, IL-6 (1 ng/mL), IL-1b (1 ng/mL), TNFa (1 ng/mL) and PGE1 (0.5 mg/mL). DCs were seeded at 2*10 4 cells / well and loaded with Geltrex or 40 Gy dissociated and irradiated tumor or healthy organoid cells (2*10 4 cells/well). Two days later, 1*10 5 T cells were added to each well and cultured for 24h. T cells were assayed for CD137 expression as described under flow cytometry.
QUANTIFICATION AND STATISTICAL ANALYSIS
Whole exome DNA sequencing data Reads were aligned to a reference genome (GRCh38). Somatic single nucleotide variations and indels were called using Somatic Sniper (Larson et al., 2012) and SomaticIndelDetector (GATK; McKenna et al., 2010) , respectively. Variants were annotated using snpEff (Cingolani et al., 2012) , version 4.3. Extra-exonic and synonymous variants were removed from further analyses. Mutational load was defined as the number of non-synonymous mutations per tumor exome. The occurrence of mutations in genes recurrently mutated in hypermutated CRC was based on the top 15 most frequently recurring significantly mutated genes according to TCGA 2012.
Live imaging
During organoid killing assays, cells were co-cultured for 3 days and imaged using a charge coupled device (CCD) camera equipped with a Zeiss AxioCam MRm camera fitted to a Zeiss Axio Observer Z1 inverted microscope. Tile scans were performed every 20 to 30 min followed by tile stitching after recording using Zen software. Videos were generated from the stitched tiles or regions of interest after background subtraction using ImageJ software version 1.50i (Schneider et al., 2012) .
Flow cytometry
Flow cytometry data were analyzed using FlowJo version 10.
Statistical analysis
Data were analyzed using GraphPad Prism version 7. Group sizes and definition of error bars is indicated in figure legends. In indicated bar graphs, background is subtracted from signal and negative values set to zero. Statistical analysis was performed using a two-tailed Student's t test. p values < 0.05 were considered significant; significance values are indicated as * (p < 0.05), ** (p < 0.01) and *** (p < 0.001).
DATA AND SOFTWARE AVAILABILITY
Whole-exome DNA sequencing data are available in Table S1 . Geltrex, or cultured for 3 days without Geltrex with Geltrex re-introduced 1 day before T cell challenge. T cells were obtained by two week co-culture with autologous tumor organoids and where indicated (lower case e) further expanded using a rapid expansion protocol (Dudley et al., 2003) , in some cases preceded by CD137-based enrichment of tumor-reactive cells (indicated by upper case E). Error bars indicate SEM of at least 2 biological replicates. Figure S5 . Time Course Imaging of NSCLC-3 Organoids Targeted by Tumor-Reactive T Cells, Related to Figure 6 Microphotograph images of NSCLC-3 organoids at indicated time points of culture with or without T cells in the presence of a green-fluorescent caspase 3/7 probe. Where indicated, MHC-I and MHC-II were blocked with W6/32 and Tü 39 antibodies, respectively. T cells are obtained by two weeks of co-culture with autologous tumor organoids followed by rapid expansion (indicated by upper case e).
